Glutaredoxin Production Cost Reports

The report provides a detailed analysis essential for establishing a glutaredoxin production plant. It encompasses all critical aspects necessary for glutaredoxin production, including the cost of glutaredoxin production, glutaredoxin plant cost, glutaredoxin production costs, and the overall glutaredoxin production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating a glutaredoxin production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.

Glutaredoxin (Grx) is a small redox enzyme, mainly utilised in biotechnology and research. It functions as a biocatalyst in enzyme assays to study protein glutathionylation/deglutathionylation, antioxidant protection, and ribonucleotide reductase activation in labs. Additionally, recombinant Grx is explored in therapeutic biotech processes for treatments targeting oxidative stress-related conditions like cancer, cardiovascular disorders, neurodegenerative diseases (e.g., Parkinson's), pulmonary issues (COPD, asthma), and inflammation, often using modified protease-resistant versions.

High-activity recombinant Grx from sources like Chlorella sorokiniana is used in food biotech for stabilising natural products or enhancing antioxidant formulations via its thiol/disulfide oxidoreductase properties. Moreover, commercially supplied His-tagged human Grx1 supports in vitro studies on DNA synthesis, signal transduction, iron-sulfur cluster biogenesis, and cellular defence against oxidative damage.

Glutaredoxin's market demand is driven by escalating R&D investments in redox biology, mainly for oxidative stress-related therapeutics targeting cancer, neurodegeneration, cardiovascular diseases, inflammation, COPD, and anti-ageing skincare formulations, as highlighted in patents for modified Grx treatments.

Additionally, research needs in iron-sulfur cluster biogenesis, antioxidant assays, and protein deglutathionylation, fuelling lab-scale purchases from suppliers like Bio-Techne, boost the market growth. Industrial glutaredoxin procurement is influenced by purity and activity levels (e.g., >95% purity, 50+ U/mg specific activity from E. coli expression), as researchers prioritise His-tagged variants for assays in redox biology, deglutathionylation studies, and iron-sulfur cluster research.

Raw Material for Glutaredoxin Production

According to the glutaredoxin production plant project report, the various raw materials for glutaredoxin production include the Grx gene and vector like pET-28a(+).

Production Process of Glutaredoxin

The extensive glutaredoxin production cost report consists of the following major industrial production process:

1. Production via recombinant DNA technology: The production process of glutaredoxin occurs through recombinant DNA technology. The process begins with cloning the Grx gene (270-321 bp) into an expression vector like pET-28a(+), followed by transformation into E. coli hosts such as BL21(DE3). The expression is induced using IPTG (0.1-1 mM) at 25-37 degree Celsius for 3-24 hours, to yield soluble protein or inclusion bodies. In the next step, the cells are lysed via sonication, and purification employs affinity chromatography (e.g., Ni-NTA or GST columns) with buffers containing 20-40 mM imidazole and 0.5 M NaCl. The process achieves 5-6 fold purity, ~44% recovery, and activities up to 53 U/mg, finally producing glutaredoxin.

Properties of Glutaredoxin

Glutaredoxin (Grx) is a small redox enzyme with a molecular weight of 12 kDa, consisting of 100-150 amino acid residues depending on the isoform (e.g., human Grx1 at ~106 residues). It has a conserved active site motif, either dithiol (CXXC, e.g., C-P-Y-C) or monothiol (CXXS), with a low pKa (~3.5) for the N-terminal active cysteine that enables efficient thiol-disulfide exchange in glutathione-dependent reactions. It adopts a thioredoxin-like fold (TRX domain, IPR011767) with a β-sheet core flanked by α-helices, existing as monomers or [2Fe-2S]-bridged dimers (e.g., Grx2) for oxidative stress sensing and stability. It is thermostable up to 50-60 degree Celsius and soluble in neutral aqueous buffers (pH 7-8) with GSH/GSSG. Grx catalyses deglutathionylation (reducing protein-SSG to protein-SH) and ribonucleotide reduction with Km ~10-50 μM for GSH-mixed disulfides, specific activity up to 53 U/mg (1 U = 1 μmol NADPH oxidised/min), and oxidation resistance via Fe-S cluster coordination in some isoforms. It is optimal at pH 6.5-8.5, with active site Cys prone to glutathionylation under high GSSG/GSH ratios, lyophilised forms stable at -20 degree Celsius, and sensitivity to proteases unless His-tagged.